1
Introduction
We report the management of a 67-year old gentleman with favorable intermediate risk
prostate adenocarcinoma treated with definitive low dose rate brachytherapy who experienced
biochemical recurrence nine years later. Although conventional imaging often fails
to definitively identify sites of disease in this context, positron emission tomography/computed
tomography (PET/CT) with small molecule radiotracers targeted against prostate-specific
membrane antigen (PSMA) have demonstrated significantly increased sensitivity for
lesion detection in patients with recurrent/metastatic prostate cancer.1, 2 This patient
was found to have a solitary lesion on PSMA-targeted 18F-DCFPyL PET/CT and was treated
with stereotactic ablative body radiotherapy (SABR) without initiation of androgen
deprivation therapy (ADT). He experienced no significant complications and prostate-specific
antigen (PSA) was undetectable at five month follow-up.
2
Case presentation
Our patient presented with a screening PSA of 5.3 ng/mL in 2007. Clinical exam demonstrated
no palpable prostate disease or lymphadenopathy (clinical T1cN0) and prostate biopsy
showed adenocarcinoma, Gleason 3 + 4 = 7 in 5% of 1 core (right apex) and 3 + 3 = 6
in 15% of 1 core (right lateral mid). He underwent low dose rate prostate brachytherapy
for his favorable intermediate risk prostate cancer, receiving 122 103Pd seeds for
a dose of 125 Gy. The patient's post-brachytherapy PSA nadir was 0.8 ng/mL.
In early 2016 his PSA rose to 3.5 ng/mL. Prostate biopsy was negative for malignancy.
Magnetic resonance imaging (MRI) of the prostate in June 2016 showed a 3.6 × 2.1 × 2.7
cm prostate with brachytherapy seeds present but without suspicious morphology, enhancement,
or restricted diffusion to suggest local recurrence and no suspicious lymphadenopathy.
Whole body 99mTc-methylene diphosphonate bone scan demonstrated no uptake suspicious
for osseous metastasis. His PSA continued to rise, reaching 4.4 in November 2016.
Repeat MRI of the pelvis and bone scan in December 2016 again showed no evidence of
recurrence or metastasis.
In January 2017 he underwent PSMA-targeted 18F-DCFPyL PET/CT which showed intense
uptake (SUVmax 21.5) in a 2.6 × 2.3 × 1.1 cm soft tissue lesion along the inferior
aspect of the right obturator internus musculature abutting the right ischiorectal
fossa which, in retrospect, could be identified on prior pelvic MRI (Fig. 1).
Fig. 1
(A) Axial PET, (B) axial CT, and (C) axial fused PET/CT images through the level of
the ischiorectal fossae demonstrate intense radiotracer uptake fusing to subtle thickening
adjacent to or within the right obturator internus musculature (red arrowheads). In
retrospect, a corresponding abnormality can be seen on MRI including increased T2
signal, minimal restricted diffusion, and early contrast enhancement (red arrowheads
on (D) axial fat-saturation T2-weighted image, (E) axial apparent diffusion coefficient
image, and (F) axial dynamic contrast-enhanced T1 image). (For interpretation of the
references to colour in this figure legend, the reader is referred to the web version
of this article.)
Fig. 1
After initial consultation, his case was presented at the interdisciplinary tumor
board at our institution. Group consensus was that his lesion would not be amenable
to resection and that local consolidation with SABR with or without long-term ADT
was reasonable. The site of presumed disease was deemed difficult to biopsy without
significant risk of morbidity and tissue confirmation was not obtained. After discussion
with the patient regarding his options, he opted to proceed with SABR in the absence
of pathological confirmation of malignancy and to forego ADT.
He underwent CT-based radiation planning including anatomic correlation of the radiotracer-avid
lesion to his planning CT. He received 36.25 Gy in 5 fractions prescribed to the 71.5%
isodose line (Fig. 2). During treatment he reported grade I fatigue and lower urinary
tract symptoms not requiring medical intervention. At 5-month follow-up, he denied
any new urinary or bowel issues and had no evidence of disease with PSA <0.1 ng/mL
and total serum testosterone of 226 ng/dL.
Fig. 2
Axial (left), sagittal (middle), and coronal (right) views of CT-based radiation plan
for delivery of SABR to 3625 cGy in 5 fractions prescribed to the 71.5% isodose line.
Radiolucent prostate brachytherapy seeds and penile prosthesis reservoir are visible
on the sagittal view.
Fig. 2
3
Discussion
This patient presented with biochemically recurrent prostate cancer without evidence
of local recurrence or distant metastases initially identified on either MRI or bone
scan. Due to the high sensitivity of PSA, biochemical failure often precedes the presence
of detectable disease as assessed by conventional imaging modalities. While emerging
modalities such as PSMA-targeted PET imaging afford higher sensitivity and thus earlier
detection of recurrence,
3
the clinical benefits of earlier intervention remain an active area of research.
While the standard of care for biochemical failure after brachytherapy without evidence
of local failure is indefinite ADT, there is no agreed-upon PSA threshold for initiation
of treatment despite an improvement in 5-year survival.
4
Additional clinical factors arguing in favor of initiating ADT, such as rapid PSA
doubling time, symptoms, or presence of detectable metastatic disease, must be weighed
against the frequent, bothersome side effects of this systemic approach which include
hot flashes, fatigue, decreased libido, erectile dysfunction, weight gain, elevated
cardiac risk, and decreased muscle mass and bone density.
Early consolidation of all macroscopic tumor deposits with SABR is a promising approach
to forestall ADT and perhaps provide a potentially curative intervention. SABR delivers
highly targeted ablative-dose radiation to targets while minimizing exposure to surrounding
organs at risk. Prior studies support metastasis-directed consolidation of low-volume
metastatic prostate cancer with SABR as safe and highly effective, with local control
rates exceeding 95%.
5
While follow-up in this case is limited, our patient has to date had minimal toxicity
and has achieved full biochemical response. Several randomized controlled trials are
now investigating the clinical benefits of stereotactic ablative radiotherapy for
patients with low-volume prostate cancer, including the Belgian STOMP (clinicaltrials.gov
identifier NCT01558427), Baltimore ORIOLE (NCT02680587), British CORE (NCT02759783),
Canadian PCS IX (NCT02685397), and French STEREO-OS (NCT03143322) trials. Continued
developments in high-sensitivity, high-specificity imaging of prostate cancer will
allow earlier target recognition and improve our likelihood of achieving total consolidation
of disease before a low-volume process progresses to widely metastatic disease requiring
systemic therapy. In this patient's case, the improved lesion detection ability of
PSMA-based 18F-DCFPyL PET/CT allowed for the appropriate selection of a treatable
lesion.
4
Conclusion
Herein we describe the use of PSMA-targeted 18F-DCFPyL PET/CT imaging to identify
a solitary recurrence of prostate cancer not initially identified by MRI and subsequently
treated with SABR. This patient achieved complete biochemical response with no significant
treatment toxicity and without initiation of ADT. This case illustrates the value
of targeted, high-precision diagnostic and therapeutic techniques as a compliment
to standard approaches to management of biochemically recurrent prostate cancer.
Funding
We acknowledge funding from the Nesbitt-McMaster Foundation, NIH CA166348, CA134675
and CA183031, Prostate Cancer Foundation (PCF) Young Investigator Award, Progenics
Pharmaceuticals and a Movember-PCF Challenge Award. The funding bodies had no involvement
in collection, analysis, or interpretation of data, in the writing of this report,
or in the decision to submit for publication.
Informed consent
Written informed consent to publish this report was obtained from the patient described
herein in accordance with Johns Hopkins Medical Institutions policy.
Conflicts of interest
MGP is a co-inventor on a US Patent covering 18F-DCFPyL, and as such is entitled to
a portion of any licensing fees and royalties generated by this technology. This arrangement
has been reviewed and approved by the Johns Hopkins University in accordance with
its conflict-of-interest policies. MAG has served as a consultant to Progenics Pharmaceuticals,
the licensee of18F-DCFPyL. MAG, SPR, MGP, and KJP have received research support from
Progenics Pharmaceuticals.